NewTradingView.com – Investing and Stock News
Investing and Stock News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Investing

Forma Therapeutics shares jump 50%; here is why

by September 3, 2022
written by September 3, 2022

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk. According to the agreement terms, Novo Nordisk will purchase the clinical-stage pharmaceutical firm focusing on rare blood disorders and sickle cell disease in a cash transaction at $20 per share, representing a total sale value of around $1.1 billion.

Transaction transform’s Forma’s clinical development of etavopivat

CEO of Forma, Frank D. Lee, said:

Today’s announcement is an exciting milestone that accelerates Forma’s purpose to transform the lives of patients with sickle cell disease and other serious hematological diseases. Novo Nordisk will partner closely with the sickle cell community to amplify our impact for patients worldwide who urgently need new treatment options.

With the purchase of Forma Therapeutics, along with its flagship experimental drug candidate, etavopivat, Novo Nordisk is advancing its scientific footprint and portfolio in hemoglobinopathies, a class of diseases in which the hemoglobin proteins in red blood cells are produced or arranged abnormally.

Rare Disease Head and EVP of Novo Nordisk Ludovic Helfgott said:

Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. By adding Forma’s differentiated approach to address unmet needs for patients, we are taking a step forward in enhancing our sickle cell disease pipeline.

Helfgott added that Novo Nordisk has an ambition of creating a top pipeline o combination and standalone therapies to address sickle cell disease’s underlying causes and complications.

Forma developing etavopivat for anemia treatment

Etavopivat is an experimental once-per-day oral exclusive pyruvate kinase-R (PKR) activator. Forma Therapeutics is developing etavopivat for treating anemia and maintaining the health of red blood cells in persons with sickle cell disease (SCD). SCD is a highly debilitating and life-threatening disease that shortens lifespan. Besides Phase 2 study for patients with Thalassemia and transfusion-dependent SCD, the drug candidate is currently undergoing a global Phase 2/3 study (Hibiscus) for SCD patients.

Lee concluded:

We look forward to working together with Novo Nordisk to serve as a trusted partner to our communities and to advance innovation, access and health equity for patients.

The post Forma Therapeutics shares jump 50%; here is why appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Meta extends partnership with Qualcomm: ‘shows weak hands for Meta’
next post
Here is why Bed Bath & Beyond shares are down 20%

You may also like

US court dismisses claim Coinbase sold unregistered securities

February 2, 2023

Ray Dalio now sees cash as ‘relatively attractive’

February 2, 2023

Peter Schiff: “Disinflation is transitory”

February 2, 2023

3 main takeaways from Chair Powell

February 2, 2023

Analyst recommends ‘caution’ as Meta stock pops 20%...

February 1, 2023

Fed just ruled out rate cuts this year:...

February 1, 2023

Jim Cramer likes only one of these two...

February 1, 2023

Analyst: buy Vodafone stock despite a slight hit...

February 1, 2023

Peloton stock shot up 20% on Wednesday: find...

February 1, 2023

IOTA promotes sustainable energy consumption with EnergieKnip

February 1, 2023
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Popular Posts

  • 1

    My Trigger to Enter $VAPR

  • 2

    Multi-Millionaire Trader Explains Why You Should Start Trading With A Small Account {VIDEO}

  • 3

    Scaling Up Tips From A 24-Year Old Millionaire Trader {VIDEO}

  • 4

    Pay Attention to These Stocks

  • 5

    New ‘Hunger Winter’ Looms as Europe Prepares to Shiver

Recent Posts

  • US court dismisses claim Coinbase sold unregistered securities

    February 2, 2023
  • Ray Dalio now sees cash as ‘relatively attractive’

    February 2, 2023
  • Should the Fed Stop Tightening?

    February 2, 2023
  • Peter Schiff: “Disinflation is transitory”

    February 2, 2023
  • The FOMC: To Pause or Not to Pause?

    February 2, 2023

Categories

  • Economy (604)
  • Editor's Pick (232)
  • Investing (1,605)
  • Stock (9)
  • About Us
  • Email Whitelisting
  • Terms and Conditions
  • Privacy Policy
  • Contacts

Disclaimer: NewTradingView.com, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2023 NewTradingView.com All Rights Reserved.


Back To Top
NewTradingView.com – Investing and Stock News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick